Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab
with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just
completed an 8 month trial of MMF treatment alone. PRA values obtained at study enrollment
and at 6 and 12 months on combined therapy as well as the rates of transplant will be
compared and evaluated using descriptive analysis.